Platinum‐Metformin Conjugates Acting as Promising PD‐L1 Inhibitors through the AMP‐Activated Protein Kinase Mediated Lysosomal Degradation Pathway
Angewandte Chemie International Edition · 02.12.2024 · 63 (49)
DOI: 10.1002/anie.202410586 ↗Kurz gefasst
Fachartikel in der Zeitschrift Angewandte Chemie International Edition, online erschienen am 25.10.2024. Verfasst von Bin Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: MOE Key Laboratory of Bioinorganic and Synthetic Chemistry Guangdong Basic Research Center of Excellence for Functional Molecular Engineering GBRCE f…. Hauptthemen laut MEDLINE: Metformin, Lysosomes, AMP-Activated Protein Kinases, B7-H1 Antigen. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 67 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
With the development of metalloimmunology, the potential of platinum drugs in cancer immunotherapy has attracted extensive attention. Although immunochemotherapy combining PD‐1/PD−L1 antibodies with platinum drugs has achieved great success in the clinic, combination therapy commonly brings new problems. Herein, we have developed a platinum‐metformin conjugate as a promising alternative to antibody‐based PD−L1 inhibitors, not only disrupting PD‐1/PD−L1 axis on cell surface but also down‐regulating the total PD−L1 levels in non‐small cell lung cancer (NSCLC) cells comprehensively, thus achieving highly efficient immunochemotherapy by a single small molecule. Mechanism studies demonstrate that Pt‐metformin conjugate can selectively accumulate in lysosomes, promote lysosomal‐dependent PD−L1 degradation via the AMPK‐TFEB pathway, and modulate the upstream regulatory proteins related to PD−L1 expression (e.g. HIF‐1α and NF‐κB), eventually decreasing the total abundance of PD−L1 in NSCLC, overcoming tumor hypoxia, and activating anti‐tumor immunity in vivo. This work suggests an AMPK‐mediated lysosomal degradation pathway of PD−L1 for the first time and provides a unique design perspective for the development of novel platinum drugs for immunochemotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- MOE Key Laboratory of Bioinorganic and Synthetic Chemistry Guangdong Basic Research Center of Excellence for Functional Molecular Engineering GBRCE for Functional Molecular Engineering School of Chemistry, Sun Yat-Sen U…
ORCID-Profile: Qian Cao, Zong-Wan Mao
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Guangdong Province
- Fundamental Research Funds for the Central Universities
- Development Program of China
Zitieren
APA
Liu, B., Liang, B. B., Cao, W. D., Su, X. X., Cao, Q., & Mao, Z. W. (2024). Platinum‐Metformin Conjugates Acting as Promising PD‐L1 Inhibitors through the AMP‐Activated Protein Kinase Mediated Lysosomal Degradation Pathway. Angewandte Chemie International Edition, 63(49). https://doi.org/10.1002/anie.202410586
Vancouver
Liu B, Liang BB, Cao WD, Su XX, Cao Q, Mao ZW. Platinum‐Metformin Conjugates Acting as Promising PD‐L1 Inhibitors through the AMP‐Activated Protein Kinase Mediated Lysosomal Degradation Pathway. Angewandte Chemie International Edition. 2024;63(49). doi:10.1002/anie.202410586
BibTeX
@article{Liu2024,
author = {Liu, Bin and Liang, Bing-Bing and Cao, Wan-Di and Su, Xu-Xian and Cao, Qian and Mao, Zong-Wan},
title = {Platinum‐Metformin Conjugates Acting as Promising PD‐L1 Inhibitors through the AMP‐Activated Protein Kinase Mediated Lysosomal Degradation Pathway},
journal = {Angewandte Chemie International Edition},
year = {2024},
volume = {63},
number = {49},
doi = {10.1002/anie.202410586}
}
EUVIMED